Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine hydrochloride is a selective α1‑adrenergic receptor agonist. When applied to the eye it stimulates the radial dilator muscle of the iris, causing contraction and pulling the pupil open. This adrenergic activation produces a prompt increase in pupil size, which is enhanced when combined with an anticholinergic agent such as tropicamide.

The exact dose of Mydriasert is determined by the prescribing ophthalmologist based on the patient’s age, ocular condition and the required degree of dilation. Typically a single drop (or the volume specified in the product labeling) is instilled in the conjunctival sac, and the prescriber may repeat the dose if additional dilation is needed. No universal dosing schedule is provided here.

Safety data for phenylephrine hydrochloride and tropicamide in pregnant or lactating women are limited. The product should only be used during pregnancy or breastfeeding if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician. Patients should discuss their individual situation with their healthcare provider.

To place an order, visit the product page on gnhindia.com, enter the required quantity of Mydriasert, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides a quotation that includes pricing, availability, shipping terms and any necessary import documentation.

Compared with single‑agent preparations such as phenylephrine alone or tropicamide alone, Mydriasert combines an α‑adrenergic agonist and an anticholinergic, delivering faster onset and longer‑lasting dilation. This synergistic effect often reduces the need for multiple drops and can improve patient comfort. However, the choice of agent depends on the clinical setting, desired duration of dilation and individual patient tolerance.

Mydriasert should be stored at room temperature, preferably below 25 °C, in its original container. The solution must be kept away from direct sunlight, excessive heat and moisture. Do not freeze the product. Once opened, follow any label‑specified beyond‑use date and discard any remaining solution that appears discolored or contaminated.

Mydriasert is applied topically to the eye. The prescriber directs the patient or healthcare professional to place the recommended number of drops into the conjunctival sac of the target eye(s). The eye should be gently closed for a few seconds to allow absorption, and the patient should avoid rubbing the eye. No systemic administration is involved.

The most serious adverse events include acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, and persistent mydriasis that may impair vision. Systemic effects such as marked hypertension or cardiac arrhythmias can also occur, particularly in patients with cardiovascular disease or when combined with other sympathomimetic drugs. Prompt medical attention is required if any of these symptoms develop.

Mydriasert is contraindicated in individuals with known hypersensitivity to phenylephrine, tropicamide or any excipients in the formulation. It should also be avoided in patients with narrow‑angle or acute angle‑closure glaucoma, severe cardiovascular disease, uncontrolled hypertension, or those taking monoamine oxidase inhibitors. Use in children should be under strict medical supervision, and the drug should not be used without a prescription from a qualified ophthalmologist.